Coagulation and Fibrinolysis During the First Year of Immunosuppressive Treatment in Renal Transplantation: Correspondence Between Hypercoagulable State and Steroid Therapy
Available accessResearch articleFirst published online September, 1995
Coagulation and Fibrinolysis During the First Year of Immunosuppressive Treatment in Renal Transplantation: Correspondence Between Hypercoagulable State and Steroid Therapy
An increased incidence of thromboembolic complications has been reported after kidney transplantation, and hypercoagulability has been associated with immunosuppressive treatment, specifically with Cyclosporin A. Hypercorticism due to prolonged steroid therapy or to Cushing's disease has been associated with a similar hypercoagulable state and thrombotic risk. The aims of this study were first to evaluate coagulation and fibrinolytic behavior in 27 patients at different times during the first year after renal transplantation and then to compare the same patients' coagulation and fibrinolytic findings 1 month after transplantation with those of a normal control group and a group of Cushing's patients. Compared with normal controls, renal transplant patients and Cushing's patients showed a similar hypercoagulable and hypofibrinolytic state, with a significant shortening in activated partial thromboplastin time and increase in factor VIII-von Willebrand factor complex, tissue plasminogen activator concentration, and plasminogen activator inhibitor activity and concentration. Other test results in the two groups showed no differences. The same abnormalities were present in the renal transplant group for the entire period of study. Our results suggest that a hypercoagulable and hypofibrinolytic state persists almost 1 year after renal transplantation and that these abnormalities are very similar to those present in Cushing's disease. Steroid treatment seems to play a key role in determining thromboembolic risk after renal transplantation. Key Words: Renal transplantation-Hypercoagulable state—von Willebrand factor-Hypofibrinolysis-Plasminogen activator inhibitor-Steroid therapy-Cyclosporin A.
References
1.
Arnadottir M. , Bergentz SE, Bergqvist D., et al. Thromboembolic complications after renal transplantation: a retrospective analysis. World J Surg1983;7:757.
2.
Bergqvist D. , Bergentz SE, Bornmyr S., et al. Deep vein thrombosis after renal transplantation: a prospective analysis of frequency and risk factors. Eur Surg Res1985;17:69.
3.
Rigotti P., Flechner SM, Van Buren CT, et al. Increased incidence of renal allograft thrombosis under cyclosporine immunosuppression. ImSurg1986;71:38.
4.
Gruber SA, Pescovitz MD, Simmons RL, et al. Thromboembolic complications in renal allograft recipients. Transplantation1987;44:775.
5.
Brunk wall J. , Bergqvist D., Bergentz SE, et al. Postoperative deep vein thrombosis after renal transplantation. Transplantation1987;43:647.
6.
Groggel GCAcute thrombosis of the renal transplant artery-a case report and a review of the literature. Clin Nephrol1991 ;36:42.
7.
Dodhia N., Rodby RA, Jensik SC, et al. Renal transplant arterial thrombosis: association with cyclosporine . Am J Kidney Dis1991;17:532.
8.
Fellström B. , Siegbahn A., Lijenberg G., et al. Primary hemostasis, plasmatic coagulation and fibrinolysis in renal transplantation. Thromb Res1990;59-97.
9.
First MR, Smith RD, Weiss MA, et al. Cyclosporine-associated glomerular and arteiolar thrombosis following renal transplantation. Transplant Proc1989;21:1567.
10.
Gruber SA, Chavers B., Payne WD, et al. Frequency of allograft renal vascular thrombosis under three immunosuppressive regimens at a single institution. Transplant Proc1989 ;21:2139.
11.
Schwieger J. , Reiss R., Cohen JL, et al. Acute renal allograft dysfunction in the setting of deep vein thrombosis: a case of successful urokinase thrombolysis and a review of the literature. Am J Kidney Dis1993;22:345.
12.
Jones RM, Murie JA, Ting A., et al. Renal vascular thrombosis of cadaveric renal allograft in patients receiving cyclosporin, azathioprine and prednisone triple therapy. Clin Transplant1988;2: 122.
Remuzzi G., Bertani T.Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis1989;13:261.
15.
Neild GH, Rocchi G., Imberti L., et al. Effect of cyclosporine A on prostacyclin release by vascular tissue. Thromb Res1983;32:373.
16.
Voss BL, Hamilton KK, Samara Ens, et al. Cyclosporine suppression of endothelial prostacyclin generation , Transplantation1988;45:793.
17.
Vanrenterghem Y., Roels L., Lerut T., et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney-allograft recipients. Lancet1985;1: 999.
18.
Cohen H., Neild GH, Patel R., et al. Evidence for chronic platelet hyperaggregability and in vivo activation in cyclosporin-treated renal allograft recipients. Thromb Res1988; 49:91.
19.
Baker Lri, Tucker B., Kovacs IBEnhanced in vitro hemostasis and reduced thrombolysis in cyclosporine-treated renal transplant recipients. Transplantation1990;49:905.
20.
Levi M., Wilmink J., Büller HR, et al. Impaired fibrinolysis in cyclosporine-treated renal transplant patients. Transplantation1992;63:188.
21.
Brown Z., Neild GH, Willoughby JJ, et al. Increased factor VIII as an index of vascular injury in cyclosporine nephrotoxicity. Transplantation1986;42:150.
22.
Huser H., Lämmle B., Landmann J., et al. Von Willebrand factor and factor VIII in renal transplant recipients under immunosuppression with cyclosporine and steroids. Clin Nephrol1990;34:214.
23.
Leitha T., Graninger W., Zazgomik J.Cyclosporine A does not increase the frequency of thromboembolic events , Transplant Proc1988;20:436.
24.
Bergentz SE , Bergqvist D., Bommyr S., et al. Venous thrombosis and cyclosporin . Lancet1985;2:101.
25.
Ozsoylu S.; Strauss HS, Diamond LKEffects of corticosteroids on coagulation of the blood. Nature1962;195:1214.
26.
Patrassi GM, Dal Bo Zanon R., Boscaro M., et al. Further studies on the hypercoagulabte state of patients with Cushing's syndrome. Thromb Haemostas1985;54:518.
27.
Patrassi GM, Sartori MT, Viero ML, et al. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coag Fibrinol1992;3:789.
28.
Rånby M., Sundell IB, Nilsson TKBlood collection in strong acid citrate anticoagulant used in a study of dietary influence on basal t-PA activity. Thromb Haemostas1989; 62:917.
29.
Girolami A. , Molaro A., Lazzarin M., et al. A new congenital haemorrhagic condition due to the presence of abnormal factor X (Factor X Friuli): study of a large kindred. Br J Haematol1970;19:179.
30.
Ness PM, Perkins HAA simple enzyme-immunoassay (EIA) test for factor VIII-related antigen (VIII-AGN) . Thromb Haemostas1979;42:848.
31.
Becker U., Bartl K., Wahjefeld AWFunctional photometric assay for plasma fibrinogen. Thromb Res1984;35:475.
32.
Soria C., Soria J., Samama MMDosage du plasminogène à l'aide d'un substrate chromogène tripeptidique . Pathol Biol1976;24:725.
33.
Wiman B., Mellbnng G., Rånby M.Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta1983 ;127:279.
34.
Holvoet P., Cleemput H., Collen D.Assay of tissue plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas1985 ;54:684.
35.
Aangles-Cano E.A spectrophotometric solid phase fibrin tissue plasminogen activator activity assay (SOFIA t-PA) for high fibrin affinity tissue plasminogen activators. Ann Biochem1986;153:201.
36.
Erikson E., Rånby M., Gyrender E., et al. Determination of plasminogen activator inhibitor in plasma using t-PA and chromogenic single point poly-D-lysine stimulated assay. Thromb Res1988;50:91.
37.
Declerck PJ , Alessi MC, Verstrekcn M., et al. Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immunoassay. Blood1988;71:220.
38.
Sjoberg HE, Blombäck M.Granberg POThromboembolic complications, heparin treatment and increase in coagulation factors in Cushing's syndrome. Acta Med Scand1976;199: 95.
39.
Seitz R., Michalik R., Karges HE, et al. Impaired fibrinolysis and protein C increase after cadaveric kidney transplantation. Thromb Res1986;42:277.
40.
Cohen H., Neild GH, Mackie IJ, et al. Persistent decreased fibrinolytic activity in cyclosporin-treated renal allograft recipients. Fibrinolysis1988 ;2:197.
41.
Rosenbaum RM , Cheli CD, Gerritsen MEDexamethasone inhibits prostaglandin release from rabbit coronary microvessel endothelium. Am J Physiol1986;250:C970.
42.
Patrassi GM , Sartori MT, Saggiorato G., et al. Familial thrombophilia associated with high levels of plasminogen activator inhibitor. Fibrinolysis1992;6:99.
Patrassi GM , Sartori MT, Viero ML, et al. Venous thrombosis and tissue plasminogen activator release deficiency: a family study. Blood Coag Fibrinol1991;2:231.
45.
Hamsten A., Wiman D.De Faire U., et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med1985; 313:1357.
46.
Schneider DJ , Nordt TK, Sobel BEAttenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes1993 ;42: 1.
47.
Hadjez JM, Combe S., Horellou MH, et al. Heterogeneous mechanisms responsible for reduced fibfinolytic capacity in patients with a history of venous thrombosis. Fibrinolysis1994;8:87.
